145 related articles for article (PubMed ID: 37325934)
1. Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.
Hu Q; Oki E; Yamada T; Kashiwada T; Sonoda H; Kataoka M; Kawanaka H; Tsuji Y; Makiyama A; Nakashima Y; Ota M; Kimura Y; Yoshizumi T
Cancer Med; 2023 Aug; 12(15):16649-16660. PubMed ID: 37325934
[TBL] [Abstract][Full Text] [Related]
2. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Pietrantonio F; Fucà G; Morano F; Gloghini A; Corso S; Aprile G; Perrone F; De Vita F; Tamborini E; Tomasello G; Gualeni AV; Ongaro E; Busico A; Giommoni E; Volpi CC; Laterza MM; Corallo S; Prisciandaro M; Antista M; Pellegrinelli A; Castagnoli L; Pupa SM; Pruneri G; de Braud F; Giordano S; Cremolini C; Di Bartolomeo M
Clin Cancer Res; 2018 Mar; 24(5):1082-1089. PubMed ID: 29208673
[No Abstract] [Full Text] [Related]
4. Association of
Hino K; Nishina T; Kajiwara T; Bando H; Nakamura M; Kadowaki S; Minashi K; Yuki S; Ohta T; Hara H; Mizukami T; Moriwaki T; Ohtsubo K; Komoda M; Mitani S; Nagashima F; Kato K; Yamada T; Hasegawa H; Yamazaki K; Yoshino T; Hyodo I
JCO Precis Oncol; 2022 Aug; 6():e2200135. PubMed ID: 35952320
[TBL] [Abstract][Full Text] [Related]
5. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
6. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
7. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
Wang DS; Liu ZX; Lu YX; Bao H; Wu X; Zeng ZL; Liu Z; Zhao Q; He CY; Lu JH; Wang ZQ; Qiu MZ; Wang F; Wang FH; Li YH; Wang XN; Xie D; Jia WH; Shao YW; Xu RH
Gut; 2019 Jul; 68(7):1152-1161. PubMed ID: 30269082
[TBL] [Abstract][Full Text] [Related]
9. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
10. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
[No Abstract] [Full Text] [Related]
11. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.
Van Bockstal MR; Agahozo MC; van Marion R; Atmodimedjo PN; Sleddens HFBM; Dinjens WNM; Visser LL; Lips EH; Wesseling J; van Deurzen CHM
Mol Oncol; 2020 Apr; 14(4):671-685. PubMed ID: 32058674
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
14. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract][Full Text] [Related]
16. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
[TBL] [Abstract][Full Text] [Related]
17. Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab.
Singla H; Kaur RP; Shafi G; Vashistha R; Banipal RPS; Kumar V; Munshi A
Mol Biol Rep; 2019 Feb; 46(1):823-831. PubMed ID: 30535550
[TBL] [Abstract][Full Text] [Related]
18. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
Kim ST; Banks KC; Pectasides E; Kim SY; Kim K; Lanman RB; Talasaz A; An J; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Park SH; Park JO; Park YS; Lim HY; Kim NKD; Park W; Lee H; Bass AJ; Kim K; Kang WK; Lee J
Ann Oncol; 2018 Apr; 29(4):1037-1048. PubMed ID: 29409051
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
